Global Rituximab Injection Market Growth 2024-2030

Global Rituximab Injection Market Growth 2024-2030

Rituximab injection sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.

The global Rituximab Injection market size is projected to grow from US$ 1469.3 million in 2023 to US$ 5565.2 million in 2030; it is expected to grow at a CAGR of 21.0% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Rituximab Injection Industry Forecast” looks at past sales and reviews total world Rituximab Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Rituximab Injection sales for 2024 through 2030. With Rituximab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Rituximab Injection industry.

This Insight Report provides a comprehensive analysis of the global Rituximab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Rituximab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Rituximab Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Rituximab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Rituximab Injection.

United States market for Rituximab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Rituximab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Rituximab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Rituximab Injection players cover Pfizer, Amgen, Roche, Celltrion and Innovent Biologics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Rituximab Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
100 ml
500 ml

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Amgen
Roche
Celltrion
Innovent Biologics
Intas Pharmaceuticals
Shanghai Henlius Biotech
Fosun-Pharmaceutical
Lexicare Pharma
Healthiza Lifescience
Kavya Pharma
Cadila Pharmaceuticals
Dr Reddy’s Laboratories
Hetero Group
Probiomed
TRPharma
Zenotech Laboratories

Key Questions Addressed in this Report

What is the 10-year outlook for the global Rituximab Injection market?

What factors are driving Rituximab Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Rituximab Injection market opportunities vary by end market size?

How does Rituximab Injection break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.